Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06880991 · ClinicalTrials.gov registry record
Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study
A clinical trial of Neurofibromatosis Type 1 and Neurofibroma, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 110
- Enrollment target
- 1
- Study location
NCT06880991 is a study of Neurofibromatosis Type 1 and Neurofibroma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 110 participants, below the 154-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06880991, a study of Neurofibromatosis Type 1 and Neurofibroma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Neurofibromatosis 1 (NF1) is a disease that causes tumors to grow along the nerves. These include plexiform neurofibromas (pNF) and cutaneous neurofibromas (cNF). Both pNF and cNF can be visible to other people. These tumors can affect a person s appearance and quality of life. Researchers want to be able to assess changes in appearance before and after treatment for NF1 tumors. Objective: To see if two questionnaires can help assess people s ratings about the appearance of their pNF and cNF tumors. Eligibility: People aged 8 years and older with pNF and people 12 years and older either with cNF or both pNF and cNF. Adult caregivers of children with pNF and cNF are also needed. Design: Participants will complete questionnaires on paper or by phone, computer, or tablet. They will answer questions about how they look, how they feel, and how they feel about the way they look. Participants will meet in at least 1 remote focus group or individual interview. The meeting will last about 1 hour. Each group will include 3 to 5 people, organized by age: 8 to 11 years, 12 to 17 years, 18 to 29 years, and over 30 years. Adult caregivers will meet in a group with other caregivers. They will discuss their NF1 symptoms; how their tumors look; how they feel about the way their tumors look; and their daily activities. They will give their opinions about 2 questionnaires about appearance. The group and individual meetings will be audio-recorded and transcribed. Information that can reveal individual identities will be removed.
Conditions Studied
Interventions
- OTHER Arm 1
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2027-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06880991
The ClinicalTrials.gov registry entry for NCT06880991 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 154-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (29% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neurofibromatosis Type 1 appearing as the primary indexed condition, and to 1 intervention - of which Arm 1 is the first listed.
NCT06880991 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06880991 about?
NCT06880991 is a clinical study titled "Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study". Background: Neurofibromatosis 1 (NF1) is a disease that causes tumors to grow along the nerves. These include plexiform neurofibromas (pNF) and cutaneous neurofibromas (cNF). Both pNF and cNF can be visible to other people. These tumors can affect a person s appearance and quality of life. Research...
What is the current status of trial NCT06880991?
This trial is currently recruiting. The enrollment target is 110 participants. The study started on 2025-04-29. Estimated completion is 2027-03-31.
What conditions does trial NCT06880991 study?
This clinical trial studies the following conditions: Neurofibromatosis Type 1, Neurofibroma.
What interventions are being tested in trial NCT06880991?
The interventions under investigation include: Arm 1 (OTHER).
Who is sponsoring clinical trial NCT06880991?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06880991 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
RECRUITING · NA
-
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
RECRUITING · NA
-
Neurofibromatosis Type 1 Tumor Early Detection Study
RECRUITING
-
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
RECRUITING · Phase 2
-
Natural History Study of Patients With Neurofibromatosis Type I
ACTIVE NOT RECRUITING
-
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.